Cardiff Posts $30.4M Nine-Month Loss; Phase 3 Slips to Q1 2027 Pending Financing
CRDF is trading near its 52-week low of $0.75 (2.6% above the low).
Summary
Cardiff reported a $30.4M net loss for the nine months ended September 30, 2026, narrower than the $38.6M loss a year earlier, with operating expenses down to $32.0M from $41.5M as R&D activity slowed ahead of the planned registrational study. For the third quarter, revenue was $171,000 and the loss was $8.86M. Cash stood at $33.8M, which management says funds operations through Q3 2027 — but the Phase 3 start, now targeted for Q1 2027, is explicitly contingent on raising additional money. The Phase 2 update is immature: median PFS in the 30 mg onvansertib arm was not reached versus roughly 11 months in the combined standard-of-care arms. The financing caveat is the crux for a company trading near its 52-week low with a going-concern warning in the last 10-Q; shareholders recently approved doubling authorized shares to 300 million, giving room to raise. Watch for a capital raise, which is the gating item before the Phase 3 trial can begin.
At the time of this announcement, CRDF was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.5M. The 52-week trading range was $0.75 to $3.31. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.